Cytotechnology
January 1993
Being able to carry zidovudine (AZT) at known concentrations into CD4+/CD38+ and CD14+ cells permits: - to reduce the drug dosage and to increase the interval for administration (until 1 dose I.V. every week); - to modulate the drug concentration into the CD4+/CD38 an CD14+ cells in relation to the "in vitro" determined HIV sensitiveness; - to eliminate haematological, medullary and general toxicity; - to be able to treat severely hill patients.
View Article and Find Full Text PDFThe Authors have studied the radiosensitivity of lymphocyte cultures of patients affected by systemic lupus erythematosus in the active phase, and in the remissive phase after treatment with cyclosporine and fluocortolone, compared to a group of normal subjects. Total lymphocyte cultures and cultures of T, B, NK lymphocytes, T helper/inducer and T suppressor cytotoxic obtained with specific monoclonal antibodies were used and then irradiated with Co-60 gamma photons at scale doses between 0 and 10 Gy. Damage due to irradiation was evaluated using 3H-TdR.
View Article and Find Full Text PDF